Delivery of Bottled Water to Women with Recurrent Urinary Tract Infections: Why in Bulgaria? - Reply

Thomas M. Hooton; Mariacristina Vecchio; Yair Lotan

doi:10.1001/jamainternmed.2018.7977

Delivery of Bottled Water to Women with Recurrent Urinary Tract Infections: Why in Bulgaria? - Reply

Thomas M. Hooton, Mariacristina Vecchio, Yair Lotan

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	449
Number of pages	1
Journal	JAMA Internal Medicine
Volume	179
Issue number	3
DOIs	https://doi.org/10.1001/jamainternmed.2018.7977
State	Published - Mar 2019

ASJC Scopus subject areas

Internal Medicine

Access to Document

10.1001/jamainternmed.2018.7977

Cite this

@article{96fd2dec8b2947a9ae3aae1fad5e6602,

title = "Delivery of Bottled Water to Women with Recurrent Urinary Tract Infections: Why in Bulgaria? - Reply",

author = "Hooton, {Thomas M.} and Mariacristina Vecchio and Yair Lotan",

note = "Funding Information: Additional Contributions: We thank Ashleigh King, MPH, The Dartmouth Institute for Health Policy and Clinical Practice, for administrative help. Her position is funded by grant 1U19HS024075 from the AHRQ Comparative Health System Performance Initiative. 1. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363(2):109-122. doi:10.1056/ NEJMoa1000485 2. Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One. 2014;9(1):e85805. doi:10.1371/journal.pone.0085805 3. Vigen R, O{\textquoteright}Donnell CI, Bar{\'o}n AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829-1836. doi:10.1001/jama.2013.280386 4. US Food and Drug Administration. FDA evaluating risk of stroke, heart attack and death with FDA-approved testosterone products. FDA Drug Safety Communication. https://www.fda.gov/downloads/Drugs/DrugSafety/ UCM383909.pdf. Published January 31, 2014. Accessed March 5, 2018. 5. The risk of cardiovascular events in men receiving testosterone therapy. An Endocrine Society statement. Chevy Chase, MD: Endocrine Society; February 7, 2014. https://www.endocrine.org/~/media/endosociety/files/ advocacy-and-outreach/position-statements/other-statements/the-risk-of-cardiovascular-events-in-men-receiving-testosterone-therapy.pdf?la=en. Accessed January 24,2018 6. US Food and Drug Administration. FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use. FDA Drug Safety Communication. https://www.fda.gov/Drugs/DrugSafety/ucm436259.htm. Accessed January 5,2018",

year = "2019",

month = mar,

doi = "10.1001/jamainternmed.2018.7977",

language = "English (US)",

volume = "179",

pages = "449",

journal = "JAMA Internal Medicine",

issn = "2168-6106",

publisher = "American Medical Association",

number = "3",

}

TY - JOUR

T1 - Delivery of Bottled Water to Women with Recurrent Urinary Tract Infections

T2 - Why in Bulgaria? - Reply

AU - Hooton, Thomas M.

AU - Vecchio, Mariacristina

AU - Lotan, Yair

N1 - Funding Information: Additional Contributions: We thank Ashleigh King, MPH, The Dartmouth Institute for Health Policy and Clinical Practice, for administrative help. Her position is funded by grant 1U19HS024075 from the AHRQ Comparative Health System Performance Initiative. 1. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363(2):109-122. doi:10.1056/ NEJMoa1000485 2. Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One. 2014;9(1):e85805. doi:10.1371/journal.pone.0085805 3. Vigen R, O’Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829-1836. doi:10.1001/jama.2013.280386 4. US Food and Drug Administration. FDA evaluating risk of stroke, heart attack and death with FDA-approved testosterone products. FDA Drug Safety Communication. https://www.fda.gov/downloads/Drugs/DrugSafety/ UCM383909.pdf. Published January 31, 2014. Accessed March 5, 2018. 5. The risk of cardiovascular events in men receiving testosterone therapy. An Endocrine Society statement. Chevy Chase, MD: Endocrine Society; February 7, 2014. https://www.endocrine.org/~/media/endosociety/files/ advocacy-and-outreach/position-statements/other-statements/the-risk-of-cardiovascular-events-in-men-receiving-testosterone-therapy.pdf?la=en. Accessed January 24,2018 6. US Food and Drug Administration. FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use. FDA Drug Safety Communication. https://www.fda.gov/Drugs/DrugSafety/ucm436259.htm. Accessed January 5,2018

PY - 2019/3

Y1 - 2019/3

UR - http://www.scopus.com/inward/record.url?scp=85062389500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062389500&partnerID=8YFLogxK

U2 - 10.1001/jamainternmed.2018.7977

DO - 10.1001/jamainternmed.2018.7977

M3 - Letter

C2 - 30830193

AN - SCOPUS:85062389500

SN - 2168-6106

VL - 179

SP - 449

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

IS - 3

ER -

Delivery of Bottled Water to Women with Recurrent Urinary Tract Infections: Why in Bulgaria? - Reply

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this